X4 Pharmaceuticals, Inc.
NASDAQ:XFORBiotechnology
+$0.06 today
- Market cap
- $304.30M
- Beta
- 0.37
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.79
Volume 0.64M
Average 0.40M
XFOR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
X4 Pharmaceuticals, Inc.NASDAQ: XFOR
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $6.97M fell 53.6% year over year, behind the -40.0% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 5.6% from the prior quarter. Over 3 fiscal years it compounded at +17.2% a year.
Context
- Selling, general & admin amounted to 123.9% of revenue in FY2025, down 2281.9 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $97.8M (+124.7%) for the fiscal year ending Dec 2026, a step up from the -29.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.97M-5.6% QoQ
- Last fiscal yearDec 2025
- $43.52M-29.3% YoY
- LTMMar 2026
- $35.46M-40.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 43.52M USD
- Year-over-year change
- -29.3%
- 4-year CAGR
- +15.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.52M | -29.3% |
| FY2024 | 2024-12-31 | 61.52M | +73.3% |
| FY2023 | 2023-12-31 | 35.51M | +31.4% |
| FY2022 | 2022-12-31 | 27.02M | +9.4% |
| FY2021 | 2021-12-31 | 24.7M | — |
Selling, General & Admin vs competitors
How XFOR compares with its peers on the latest reported figures
- XFOR's LTM Mar 2026 selling, general & admin of $35.46M is the 2nd highest of the 4 companies compared; the peer median is $14.61M.
- Its year-over-year change of -40.0% is the lowest of 4, against a peer median of +9.3%.
- Selling, general & admin amounts to 393.4% of revenue for XFOR, versus a peer median of 69.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $104.54M | -7.7% | -10.2% | 69.2% | |
| LTM Mar 2026 | $35.46M | -40.0% | +17.2% | 393.4% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $14.61M | +87.7% | +55.5% | — |
| LTM Mar 2026 | $10.25M | +9.3% | +3.5% | — | |
| Peer median (excluding XFOR) | $14.61M | +9.3% | +3.5% | 69.2% | |
Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.56M | 35.11M |
| Cost of Revenue | 1.89M | 0 | 0 | 797K | 6.26M |
| Gross Profit | (1.89M) | 0 | 0 | 1.76M | 28.86M |
| Gross Margin | — | — | — | 68.8% | 82.2% |
| Research & Development | 48.76M | 61.06M | 72.02M | 81.64M | 72.22M |
| Selling, General & Admin | 24.7M | 27.02M | 35.51M | 61.52M | 43.52M |
| Operating Expenses | 73.46M | 87.57M | 107.52M | 38.16M | 115.74M |
| Depreciation & Amortization | 1.89M | 513K | 419K | 796K | 1.28M |
| EBITDA | (83.15M) | (89.33M) | (94.89M) | (27.58M) | (69.01M) |
| EBITDA Margin | — | — | — | -1078.5% | -196.5% |
| Operating Income | (75.35M) | (87.57M) | (107.52M) | (36.4M) | (86.88M) |
| Operating Margin | — | — | — | -1423.6% | -247.4% |
| Interest Income | 10K | 219K | 4.58M | 5.77M | 4.58M |
| Interest Expense | 3.64M | 3.99M | 5.78M | 8.77M | 8.88M |
| Other Income / Expenses | (13.33M) | (6.27M) | 6.43M | (739K) | 7.73M |
| Income Before Tax | (88.68M) | (93.84M) | (101.09M) | (37.14M) | (79.16M) |
| Pre-Tax Margin | — | — | — | -1452.5% | -225.4% |
| Income Tax Expense | 17K | 28K | 78K | 310K | 41K |
| Net Income | (88.7M) | (93.87M) | (101.17M) | (37.45M) | (79.2M) |
| Net Margin | — | — | — | -1464.6% | -225.6% |
| EPS (Basic) | (119.58) | (45.60) | (17.07) | (5.59) | (1.87) |
| EPS (Diluted) | (119.58) | (45.60) | (17.07) | (5.59) | (1.87) |
| Weighted Avg Shares | 858.3K | 2.12M | 5.93M | 6.7M | 42.29M |
| Weighted Avg Shares (Diluted) | 858.3K | 2.12M | 5.93M | 6.7M | 42.29M |
X4 Pharmaceuticals, Inc.
NASDAQ:XFOR
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.